

Cornelia Lass-Flögel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3806657/publications.pdf>

Version: 2024-02-01

276
papers

12,665
citations

30070

54
h-index

36028

97
g-index

283
all docs

283
docs citations

283
times ranked

10905
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e149-e162.	9.1	586
2	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. <i>Haematologica</i> , 2017, 102, 433-444.	3.5	468
3	EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). <i>Clinical Microbiology and Infection</i> , 2012, 18, E246-E247.	6.0	368
4	The changing face of epidemiology of invasive fungal disease in Europe. <i>Mycoses</i> , 2009, 52, 197-205.	4.0	351
5	Antifungal drug resistance among <i>Candida</i> species: mechanisms and clinical impact. <i>Mycoses</i> , 2015, 58, 2-13.	4.0	314
6	COVID-19 Associated Pulmonary Aspergillosis (CAPA) – From Immunology to Treatment. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 91.	3.5	292
7	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	8.2	278
8	Human Protothecosis. <i>Clinical Microbiology Reviews</i> , 2007, 20, 230-242.	13.6	272
9	High-frequency Triazole Resistance Found In Nonculturable <i>Aspergillus fumigatus</i> from Lungs of Patients with Chronic Fungal Disease. <i>Clinical Infectious Diseases</i> , 2011, 52, 1123-1129.	5.8	264
10	Epidemiology and outcome of infections due to <i>Aspergillus terreus</i> : 10-year single centre experience. <i>British Journal of Haematology</i> , 2005, 131, 201-207.	2.5	252
11	Environmental Study of Azole-Resistant <i>Aspergillus fumigatus</i> and Other Aspergilli in Austria, Denmark, and Spain. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4545-4549.	3.2	217
12	Triazole Antifungal Agents in Invasive Fungal Infections. <i>Drugs</i> , 2011, 71, 2405-2419.	10.9	217
13	IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. <i>Nature Communications</i> , 2016, 7, 10791.	12.8	201
14	The Value of Computed Tomography-Guided Percutaneous Lung Biopsy for Diagnosis of Invasive Fungal Infection in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2007, 45, e101-e104.	5.8	200
15	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. <i>Drugs</i> , 2021, 81, 1703-1729.	10.9	168
16	Diagnosing COVID-19-associated pulmonary aspergillosis. <i>Lancet Microbe</i> , The, 2020, 1, e53-e55.	7.3	158
17	Proposed nomenclature for <i>Pseudallescheria</i> , <i>Scedosporium</i> and related genera. <i>Fungal Diversity</i> , 2014, 67, 1-10.	12.3	152
18	Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3637-3641.	3.2	138

#	ARTICLE	IF	CITATIONS
19	Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2268-2273.	3.0	131
20	Defining breakthrough invasive fungal infection – Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. <i>Mycoses</i> , 2019, 62, 716-729.	4.0	129
21	Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium. <i>Antibiotics</i> , 2020, 9, 877.	3.7	125
22	Potential Basis for Amphotericin B Resistance in <i>Aspergillus terreus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1553-1555.	3.2	116
23	Development and Validation of a Rapid, Single-Step Reverse Transcriptase Loop-Mediated Isothermal Amplification (RT-LAMP) System Potentially to Be Used for Reliable and High-Throughput Screening of COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 331.	3.9	113
24	Detection and investigation of invasive mould disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, i15-i24.	3.0	111
25	Breakthrough <i>Aspergillus fumigatus</i> and <i>Candida albicans</i> Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1185-1193.	3.2	110
26	A mast cell-IILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. <i>Nature Communications</i> , 2017, 8, 14017.	12.8	110
27	Diagnosing Invasive Aspergillosis during Antifungal Therapy by PCR Analysis of Blood Samples. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4154-4157.	3.9	107
28	Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against <i>Candida</i> spp. and triazoles against <i>Aspergillus</i> spp.. <i>Drug Resistance Updates</i> , 2013, 16, 81-95.	14.4	106
29	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	8.2	106
30	Laboratory diagnosis of mucormycosis: current status and future perspectives. <i>Future Microbiology</i> , 2014, 9, 683-695.	2.0	105
31	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. <i>Haematologica</i> , 2013, 98, e127-e130.	3.5	99
32	Establishing In Vitro-In Vivo Correlations for <i>Aspergillus fumigatus</i> : the Challenge of Azoles versus Echinocandins. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3504-3511.	3.2	98
33	Screening for <i>Aspergillus</i> spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. <i>British Journal of Haematology</i> , 2001, 113, 180-184.	2.5	94
34	Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. <i>International Journal of Hematology</i> , 2008, 88, 508-515.	1.6	94
35	The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 138.	3.5	84
36	Changes in the epidemiological landscape of invasive mould infections and disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i5-i11.	3.0	82

#	ARTICLE	IF	CITATIONS
37	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	9.1	80
38	Molecular analysis of <i>cyp51</i> from fluconazole-resistant <i>Candida albicans</i> strains. <i>FEMS Microbiology Letters</i> , 2006, 151, 263-268.	1.8	78
39	In Vitro Activity of Isavuconazole against <i>Aspergillus</i> Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1645-1647.	3.2	77
40	Human Platelets Attenuate <i>Aspergillus</i> Species via Granule-Dependent Mechanisms. <i>Journal of Infectious Diseases</i> , 2008, 198, 1243-1246.	4.0	71
41	<i>Aspergillus alabamensis</i> , a New Clinically Relevant Species in the Section <i>Terrei</i> . <i>Eukaryotic Cell</i> , 2009, 8, 713-722.	3.4	67
42	Minireview: host defence in invasive aspergillosis. <i>Mycoses</i> , 2013, 56, 403-413.	4.0	66
43	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. <i>Frontiers in Microbiology</i> , 2018, 9, 516.	3.5	66
44	Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. <i>Critical Care</i> , 2015, 19, 178.	5.8	65
45	Determination of Isavuconazole Susceptibility of <i>Aspergillus</i> and <i>Candida</i> Species by the EUCAST Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5426-5431.	3.2	64
46	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an <i>Aspergillus</i> PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. <i>European Journal of Haematology</i> , 2012, 89, 120-127.	2.2	63
47	Whole-Genome Sequencing of the Opportunistic Yeast Pathogen <i>Candida inconspicua</i> Uncovers Its Hybrid Origin. <i>Frontiers in Genetics</i> , 2019, 10, 383.	2.3	63
48	Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2636-2638.	3.2	62
49	In Vitro Activities of Various Antifungal Drugs against <i>Aspergillus terreus</i> : Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility Testing. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 794-795.	3.2	62
50	New Insight into Amphotericin B Resistance in <i>Aspergillus terreus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1583-1588.	3.2	62
51	Complement and platelets: Mutual interference in the immune network. <i>Molecular Immunology</i> , 2015, 67, 108-118.	2.2	62
52	Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. <i>Journal of Medical Microbiology</i> , 2016, 65, 1414-1421.	1.8	62
53	Improving outcome of fungal diseases – Guiding experts and patients towards excellence. <i>Mycoses</i> , 2017, 60, 420-425.	4.0	61
54	EQUAL <i>Candida</i> Score: An ECMM score derived from current guidelines to measure QUALity of Clinical <i>Candidaemia</i> Management. <i>Mycoses</i> , 2018, 61, 326-330.	4.0	60

#	ARTICLE	IF	CITATIONS
55	Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14 α -demethylase. <i>Scientific Reports</i> , 2017, 7, 15898.	3.3	59
56	First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant <i>Candida parapsilosis</i> Isolates Harboring Y132F and/or Y132F+K143R in Turkey. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	57
57	Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease - review of the literature. <i>European Journal of Medical Research</i> , 2011, 16, 153.	2.2	56
58	In Vivo Emergence of <i>Aspergillus terreus</i> with Reduced Azole Susceptibility and a Cyp51a M217I Alteration. <i>Journal of Infectious Diseases</i> , 2012, 206, 981-985.	4.0	55
59	How to make a fast diagnosis in invasive aspergillosis. <i>Medical Mycology</i> , 2019, 57, S155-S160.	0.7	55
60	Utility of PCR in Diagnosis of Invasive Fungal Infections: Real-Life Data from a Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 863-868.	3.9	54
61	Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis in Solid Organ Transplant Patients. <i>Transplantation</i> , 2014, 98, 898-902.	1.0	54
62	<i>Galleria mellonella</i> as a host model to study <i>Aspergillus terreus</i> virulence and amphotericin B resistance. <i>Virulence</i> , 2015, 6, 591-598.	4.4	54
63	<i>Galleria mellonella</i> as a model system to study virulence potential of mucormycetes and evaluation of antifungal treatment. <i>Medical Mycology</i> , 2019, 57, 351-362.	0.7	54
64	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. <i>Mycoses</i> , 2019, 62, 310-319.	4.0	53
65	Proof of Concept for MBT ASTRA, a Rapid Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS)-Based Method To Detect Caspofungin Resistance in <i>Candida albicans</i> and <i>Candida glabrata</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	52
66	Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. <i>Mycoses</i> , 2018, 61, 885-894.	4.0	52
67	Galactosaminogalactan (GAG) and its multiple roles in <i>Aspergillus</i> pathogenesis. <i>Virulence</i> , 2019, 10, 976-983.	4.4	52
68	Serology anno 2021—fungal infections: from invasive to chronic. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1230-1241.	6.0	52
69	In vitro susceptibility testing in fungi: a global perspective on a variety of methods. <i>Mycoses</i> , 2010, 53, 1-11.	4.0	51
70	Diagnostic accuracy of the <i>Aspergillus</i> -specific bronchoalveolar lavage lateral-flow assay in haematological malignancy patients. <i>Mycoses</i> , 2015, 58, 461-469.	4.0	51
71	<i>Aspergillus terreus</i> : Novel lessons learned on amphotericin B resistance. <i>Medical Mycology</i> , 2018, 56, S73-S82.	0.7	50
72	Up-date on Diagnostic Strategies of Invasive Aspergillosis. <i>Current Pharmaceutical Design</i> , 2013, 19, 3595-3614.	1.9	50

#	ARTICLE	IF	CITATIONS
73	Molecular Typing of <i>Aspergillus terreus</i> Isolates Collected in Houston, Texas, and Innsbruck, Austria: Evidence of Great Genetic Diversity. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2686-2690.	3.9	49
74	Platelet immunology in fungal infections. <i>Thrombosis and Haemostasis</i> , 2014, 112, 632-639.	3.4	49
75	Disseminated Infection with <i>Prototheca zoppii</i> after Unrelated Stem Cell Transplantation for Leukemia. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4907-4908.	3.9	48
76	<i>Aspergillus</i> -Specific Lateral-Flow Device and Real-Time PCR Testing of Bronchoalveolar Lavage Fluid: a Combination Biomarker Approach for Clinical Diagnosis of Invasive Pulmonary Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2103-2108.	3.9	45
77	In vitro resistance of clinical <i>Fusarium</i> species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 438-443.	1.8	45
78	Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells. <i>PLoS Pathogens</i> , 2015, 11, e1005005.	4.7	44
79	Generation of Human Monocyte-derived Dendritic Cells from Whole Blood. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	44
80	Evaluation of Molecular Epidemiology, Clinical Characteristics, Antifungal Susceptibility Profiles, and Molecular Mechanisms of Antifungal Resistance of Iranian <i>Candida parapsilosis</i> Species Complex Blood Isolates. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 206.	3.9	44
81	Incidence of Cyp51 A Key Mutations in <i>Aspergillus fumigatus</i> —A Study on Primary Clinical Samples of Immunocompromised Patients in the Period of 1995–2013. <i>PLoS ONE</i> , 2014, 9, e103113.	2.5	44
82	EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS IN THE MEDITERRANEAN AREA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011016.	1.3	43
83	Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 66.	3.5	43
84	YEAST PANEL multiplex PCR for identification of clinically important yeast species: stepwise diagnostic strategy, useful for developing countries. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 112-119.	1.8	42
85	<i>Candida albicans</i> Hgt1p, a Multifunctional Evasion Molecule: Complement Inhibitor, CR3 Analogue, and Human Immunodeficiency Virus—Binding Molecule. <i>Journal of Infectious Diseases</i> , 2011, 204, 802-809.	4.0	41
86	C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2–infected primary human airway epithelia. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2083-2097.e6.	2.9	41
87	Blocking Hsp70 Enhances the Efficiency of Amphotericin B Treatment against Resistant <i>Aspergillus terreus</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3778-3788.	3.2	40
88	EUCAST breakpoints for antifungals. <i>Drug News and Perspectives</i> , 2010, 23, 93.	1.5	40
89	<i>Candida tropicalis</i> is the most prevalent yeast species causing candidemia in Algeria: the urgent need for antifungal stewardship and infection control measures. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 50.	4.1	39
90	<sc>EUCAST</sc> Technical Note on <i>Candida</i> and micafungin, anidulafungin and fluconazole. <i>Mycoses</i> , 2014, 57, 377-379.	4.0	38

#	ARTICLE	IF	CITATIONS
91	Novel multiplex real-time quantitative PCR detecting system approach for direct detection of <i>Candida auris</i> and its relatives in spiked serum samples. <i>Future Microbiology</i> , 2019, 14, 33-45.	2.0	38
92	Microbiological and Molecular Diagnosis of Mucormycosis: From Old to New. <i>Microorganisms</i> , 2021, 9, 1518.	3.6	38
93	Bronchoalveolar Lavage Fluid (1,3) β -D-Glucan for the Diagnosis of Invasive Fungal Infections in Solid Organ Transplantation. <i>Transplantation</i> , 2015, 99, e140-e144.	1.0	37
94	IL-10 overexpression predisposes to invasive aspergillosis by suppressing antifungal immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 867-870.e9.	2.9	37
95	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1807-1819.	3.0	37
96	Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 684014.	4.8	37
97	Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study. <i>European Journal of Haematology</i> , 2015, 94, 258-264.	2.2	35
98	Phylogenetic diversity of human pathogenic <i>Fusarium</i> and emergence of uncommon virulent species. <i>Journal of Infection</i> , 2015, 71, 658-666.	3.3	35
99	Pan-azole-resistant <i>Candida tropicalis</i> carrying homozygous <i>erg11</i> mutations at position K143R: a new emerging superbug?. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw558.	3.0	35
100	The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. <i>Lancet Microbe</i> , The, 2022, 3, e464-e470.	7.3	35
101	Natural killer cell-mediated damage of clinical isolates of mucormycetes. <i>Mycoses</i> , 2016, 59, 34-38.	4.0	34
102	Low level of antifungal resistance of <i>Candida glabrata</i> blood isolates in Turkey: Fluconazole minimum inhibitory concentration and <i>FKS</i> mutations can predict therapeutic failure. <i>Mycoses</i> , 2020, 63, 911-920.	4.0	34
103	Clonal Candidemia Outbreak by <i>Candida parapsilosis</i> Carrying Y132F in Turkey: Evolution of a Persisting Challenge. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 676177.	3.9	34
104	Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1368-1374.e2.	2.9	33
105	<i>In vitro</i> susceptibility testing in <i>Aspergillus</i> species: an update. <i>Future Microbiology</i> , 2010, 5, 789-799.	2.0	32
106	Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within <i>Aspergillus</i> section <i>Terrei</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3068-3073.	3.0	32
107	Characterization of the Cellular Immune Responses to <i>Rhizopus oryzae</i> With Potential Impact on Immunotherapeutic Strategies in Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2012, 206, 135-139.	4.0	31
108	Invasive pulmonary Aspergillosis in organ transplants – Focus on lung transplants. <i>Respiratory Investigation</i> , 2016, 54, 76-84.	1.8	31

#	ARTICLE	IF	CITATIONS
109	Current Challenges in the Diagnosis of Fungal Infections. <i>Methods in Molecular Biology</i> , 2017, 1508, 3-15.	0.9	31
110	Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. <i>Klinische Bewertung der Aspergillus-PCR zum Nachweis der invasiven Aspergillose bei immunsupprimierten Patienten. Mycoses</i> , 2005, 48, 12-17.	4.0	30
111	Treatment of Infections Due to Aspergillus terreus Species Complex. <i>Journal of Fungi (Basel)</i> , 2021, 7, 103-114. <small>TJ ETQq1 1 0.784314 rgBT /Overlock 10</small>	3.5	30
112	The changing spectrum of Saccharomycotina yeasts causing candidemia: phylogeny mirrors antifungal susceptibility patterns for azole drugs and amphotericin B. <i>FEMS Yeast Research</i> , 2019, 19, .	2.3	30
113	Etest Cannot Be Recommended for <i>In Vitro</i> Susceptibility Testing of Mucorales. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3663-3665.	3.2	29
114	Oxidative Stress Response Tips the Balance in Aspergillus terreus Amphotericin B Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	29
115	In vitro antifungal activity of amphotericin B and 11 comparators against <i>Aspergillus terreus</i> species complex. <i>Mycoses</i> , 2018, 61, 134-142.	4.0	29
116	Genetically related micafungin-resistant <i>Candida parapsilosis</i> blood isolates harbouring novel mutation R658C in hotspot 1 of Fks1p: a new challenge?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 418-422.	3.0	29
117	New Insights into Invasive Aspergillosis - from the Pathogen to the Disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 3679-3688.	1.9	29
118	First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 336-339.	1.8	28
119	Salmonella Utilizes Zinc To Subvert Antimicrobial Host Defense of Macrophages via Modulation of NF- κ B Signaling. <i>Infection and Immunity</i> , 2017, 85, .	2.2	28
120	Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method. <i>International Journal of Antimicrobial Agents</i> , 2003, 21, 229-233.	2.5	27
121	Invasive Pulmonary Mycosis Due to Penicillium chrysogenum. <i>Transplantation</i> , 2013, 95, e21-e23.	1.0	27
122	De Novo Whole-Genome Sequence and Genome Annotation of Lichtheimia ramosa. <i>Genome Announcements</i> , 2014, 2, .	0.8	27
123	Antifungal resistance in Aspergillus terreus: A current scenario. <i>Fungal Genetics and Biology</i> , 2019, 131, 103247.	2.1	27
124	Susceptibility Testing of Anidulafungin and Voriconazole Alone and in Combination against Conidia and Hyphae of <i>Aspergillus</i> spp. under Hypoxic Conditions. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1873-1875.	3.2	26
125	Interaction of sertraline with Candida species selectively attenuates fungal virulence in vitro. <i>FEMS Immunology and Medical Microbiology</i> , 2003, 35, 11-15.	2.7	25
126	The role of complement in invasive fungal infections. <i>Die Rolle des Komplements bei invasiven Pilzinfektionen. Mycoses</i> , 2004, 47, 93-103.	4.0	25

#	ARTICLE	IF	CITATIONS
127	Amphotericin B Resistance in <i>Aspergillus terreus</i> Is Overpowered by Coapplication of Pro-oxidants. Antioxidants and Redox Signaling, 2015, 23, 1424-1438.	5.4	25
128	Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1704-1712.	3.0	25
129	Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is <i>Aspergillus</i> ?. Medical Mycology, 2017, 55, myw093.	0.7	24
130	Perspectives on <i>Scedosporium</i> species and <i>Lomentospora prolificans</i> in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology. Transplant Infectious Disease, 2019, 21, e13141.	1.7	24
131	<i>Candida albicans</i> Factor H Binding Molecule Hgt1p – A Low Glucose-Induced Transmembrane Protein Is Trafficked to the Cell Wall and Impairs Phagocytosis and Killing by Human Neutrophils. Frontiers in Microbiology, 2019, 9, 3319.	3.5	24
132	Posaconazole Enhances the Activity of Amphotericin B against <i>Aspergillus</i> Hyphae In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 791-793.	3.2	23
133	The leucine biosynthetic pathway is crucial for adaptation to iron starvation and virulence in <i>Aspergillus fumigatus</i> . Virulence, 2019, 10, 925-934.	4.4	23
134	Invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infections in pediatric patients: Analysis of 55 cases from FungiScope® and the literature. International Journal of Infectious Diseases, 2020, 92, 114-122.	3.3	23
135	<i>Aspergillus terreus</i> Species Complex. Clinical Microbiology Reviews, 2021, 34, e0031120.	13.6	23
136	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. Journal of Allergy and Clinical Immunology, 2022, 149, 1242-1252.e12.	2.9	23
137	Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opinion on Investigational Drugs, 2022, 31, 795-812.	4.1	23
138	Short Communication - Antifungal properties of 5-hydroxytryptamine (serotonin) against <i>Aspergillus</i> spp. in vitro. International Journal of Medical Microbiology, 2002, 291, 655-657.	3.6	22
139	<i>In vitro</i> susceptibility testing in <i>Aspergillus</i> species. Mycoses, 2008, 51, 437-446.	4.0	22
140	Immediate T-Helper 17 Polarization Upon Triggering CD11b/c on HIV-Exposed Dendritic Cells. Journal of Infectious Diseases, 2015, 212, 44-56.	4.0	22
141	Promising immunotherapy against fungal diseases. Expert Opinion on Biological Therapy, 2017, 17, 861-870.	3.1	22
142	The Emergence of Rare Clinical <i>Aspergillus</i> Species in Qatar: Molecular Characterization and Antifungal Susceptibility Profiles. Frontiers in Microbiology, 2019, 10, 1677.	3.5	22
143	Antifungal susceptibility profiles of rare ascomycetous yeasts. Journal of Antimicrobial Chemotherapy, 2019, 74, 2649-2656.	3.0	22
144	Diagnosing and monitoring of invasive aspergillosis during antifungal therapy by polymerase chain reaction: an experimental study in mice. Diagnostic Microbiology and Infectious Disease, 2003, 47, 569-572.	1.8	21

#	ARTICLE	IF	CITATIONS
145	The Mediterranean red alga <i>Asparagopsis taxiformis</i> has antifungal activity against <i>Aspergillus</i> species. <i>Mycoses</i> , 2013, 56, 516-519.	4.0	21
146	Recent Increase in the Prevalence of Fluconazole-Non-susceptible <i>Candida tropicalis</i> Blood Isolates in Turkey: Clinical Implication of Azole-Non-susceptible and Fluconazole Tolerant Phenotypes and Genotyping. <i>Frontiers in Microbiology</i> , 2020, 11, 587278.	3.5	21
147	Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 216.	3.5	21
148	<i>Candida</i> and Complement: New Aspects in an Old Battle. <i>Frontiers in Immunology</i> , 2020, 11, 1471.	4.8	21
149	Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development. <i>Cancers</i> , 2021, 13, 3431.	3.7	21
150	<i>Aspergillus fumigatus</i> responds to natural killer (NK) cells with upregulation of stress related genes and inhibits the immunoregulatory function of NK cells. <i>Oncotarget</i> , 2016, 7, 71062-71071.	1.8	21
151	In Vitro Activities of Amphotericin B and Voriconazole against <i>Aleurioconidia</i> from <i>Aspergillus terreus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2539-2540.	3.2	20
152	Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 127-135.	4.4	20
153	Long term complications following 54 consecutive lung transplants. <i>Journal of Thoracic Disease</i> , 2016, 8, 1234-1244.	1.4	20
154	Precise genome editing using a CRISPR-Cas9 method highlights the role of CoERG11 amino acid substitutions in azole resistance in <i>Candida orthopsilosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2230-2238.	3.0	20
155	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope™ Global Registry for Emerging Fungal Infections. <i>Journal of Infection</i> , 2020, 81, 802-815.	3.3	20
156	Antifungal properties of 5-hydroxytryptamine (serotonin) against <i>Candida</i> species in vitro. <i>Journal of Medical Microbiology</i> , 2003, 52, 169-171.	1.8	19
157	Treatment of drug-resistant <i>Aspergillus</i> infection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2267-2270.	1.8	19
158	Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against <i>Candida</i> Species from a Single Center in Austria. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	19
159	Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience. <i>Infection</i> , 2017, 45, 867-875.	4.7	19
160	ECMM <i>Candida</i> RegA: A ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019, 62, 920-927.	4.0	19
161	Evaluation of a Novel Mitochondrial Pan-Mucorales Marker for the Detection, Identification, Quantification, and Growth Stage Determination of Mucormycetes. <i>Journal of Fungi (Basel)</i> , 2020, 6, 1071.	0.784314	10
162	Diagnostic Performance of a Novel Multiplex PCR Assay for Candidemia among ICU Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 86.	3.5	19

#	ARTICLE	IF	CITATIONS
163	In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against <i>Aspergillus conidia</i> and hyphae . In vitro-Empfindlichkeit von <i>Aspergillus</i> -Konidien und -Hyphen gegenüber Amphotericin B und Amphotericin B-Lipidpreparationen. <i>Mycoses</i> , 2002, 45, 166-169.	4.0	18
164	Invasive candidiasis: future directions in non-culture based diagnosis. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 829-838.	4.4	18
165	A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women. <i>Frontiers in Microbiology</i> , 2021, 12, 655069.	3.5	18
166	A point prevalence survey on hand hygiene, with a special focus on <i>Candida</i> species. <i>American Journal of Infection Control</i> , 2016, 44, 71-73.	2.3	17
167	Anidulafungin Susceptibility Testing of <i>Candida glabrata</i> Isolates from Blood Cultures by the MALDI Biotyper Antibiotic (Antifungal) Susceptibility Test Rapid Assay. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
168	<i>Candida</i> : Platelet Interaction and Platelet Activity in vitro. <i>Journal of Innate Immunity</i> , 2019, 11, 52-62.	3.8	17
169	Novel Antifungal Agents and Their Activity against <i>Aspergillus</i> Species. <i>Journal of Fungi (Basel,)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.5	17
170	Interaction of 5-hydroxytryptamine (serotonin) against <i>Aspergillus</i> spp. in vitro. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 424-429.	2.5	16
171	Susceptibility of <i>Candida</i> species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey. <i>Medical Mycology</i> , 2011, 49, 856-863.	0.7	16
172	Assessing micafungin/triazole combinations for the treatment of invasive scedosporiosis due to <i>Scedosporium apiospermum</i> and <i>Scedosporium boydii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3027-3032.	3.0	16
173	Generation of A <i>Mucor circinelloides</i> Reporter Strainâ€”A Promising New Tool to Study Antifungal Drug Efficacy and Mucormycosis. <i>Genes</i> , 2018, 9, 613.	2.4	16
174	Outbreak report: a nosocomial outbreak of vancomycin resistant enterococci in a solid organ transplant unit. <i>Antimicrobial Resistance and Infection Control</i> , 2018, 7, 86.	4.1	16
175	Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans. <i>Frontiers in Immunology</i> , 2019, 10, 890.	4.8	16
176	High percentage of microbial colonization of osteosynthesis material in clinically unremarkable patients. <i>MicrobiologyOpen</i> , 2019, 8, e00658.	3.0	16
177	Antifungal susceptibility of yeast bloodstream isolates collected during a 10â€”year period in Austria. <i>Mycoses</i> , 2019, 62, 357-367.	4.0	16
178	Epidemiology of invasive fungal infections in the mediterranean area. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e20110016.	1.3	16
179	Diagnosing invasive fungal diseases â€” limitations of microbiological diagnostic methods. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 461-470.	1.6	15
180	Susceptibility Profiles of Amphotericin B and Posaconazole against Clinically Relevant Mucorales Species under Hypoxic Conditions. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1344-1346.	3.2	15

#	ARTICLE	IF	CITATIONS
181	Sterol Composition of Clinically Relevant Mucorales and Changes Resulting from Posaconazole Treatment. <i>Molecules</i> , 2018, 23, 1218.	3.8	15
182	ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia. <i>MBio</i> , 2021, 12, .	4.1	15
183	Virulence and thrombocyte affectation of two <i>Aspergillus terreus</i> isolates differing in amphotericin B susceptibility. <i>Medical Microbiology and Immunology</i> , 2013, 202, 379-389.	4.8	14
184	Voriconazole MICs are predictive for the outcome of experimental disseminated scedosporiosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw532.	3.0	14
185	Cryptic species of <i>Aspergillus</i> section <i>Terrei</i> display essential physiological features to cause infection and are similar in their virulence potential in <i>Galleria mellonella</i> . <i>Virulence</i> , 2019, 10, 542-554.	4.4	14
186	Turning the World Upside-Down in Cellulose for Improved Culturing and Imaging of Respiratory Challenges within a Human 3D Model. <i>Cells</i> , 2019, 8, 1292.	4.1	14
187	Efficacy of LAMB against Emerging Azole- and Multidrug-Resistant <i>Candida parapsilosis</i> Isolates in the <i>Galleria mellonella</i> Model. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 377.	3.5	14
188	Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 816-824.	2.5	14
189	Elevated minimum inhibitory concentrations to antifungal drugs prevail in 14 rare species of candidemia-causing <i>Saccharomycotina</i> yeasts. <i>Medical Mycology</i> , 2020, 58, 987-995.	0.7	14
190	MixInYeast: A Multicenter Study on Mixed Yeast Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 13.	3.5	14
191	Platelets enhance activity of antimycotic substances against non- <i>Aspergillus fumigatus</i> <i>Aspergillus</i> species in vitro. <i>Medical Mycology</i> , 2011, 49, 157-166.	0.7	13
192	Necrotizing mycosis due to <i>Verruconis gallopava</i> in an immunocompetent patient. <i>Infection</i> , 2015, 43, 743-746.	4.7	13
193	Common Genetic Polymorphisms within NF- κ B-Related Genes and the Risk of Developing Invasive Aspergillosis. <i>Frontiers in Microbiology</i> , 2016, 7, 1243.	3.5	13
194	A Retrospective Assessment of Four Antigen Assays for the Detection of Invasive Candidiasis Among High-Risk Hospitalized Patients. <i>Mycopathologia</i> , 2018, 183, 513-519.	3.1	13
195	β -1,3-glucan-lacking <i>Aspergillus fumigatus</i> mediates an efficient antifungal immune response by activating complement and dendritic cells. <i>Virulence</i> , 2019, 10, 957-969.	4.4	13
196	Candidemia Among Coronavirus Disease 2019 Patients in Turkey Admitted to Intensive Care Units: A Retrospective Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac078.	0.9	13
197	Human immunodeficiency virus type 1 Tat binds to <i>Candida albicans</i> , inducing hyphae but augmenting phagocytosis in vitro. <i>Immunology</i> , 2001, 104, 455-461.	4.4	12
198	EUCAST Testing of Isavuconazole Susceptibility in <i>Aspergillus</i> : Comparison of Results for Inoculum Standardization Using Conidium Counting versus Optical Density. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6432-6436.	3.2	12

#	ARTICLE	IF	CITATIONS
199	Effect of Reduced Oxygen on the Antifungal Susceptibility of Clinically Relevant Aspergilli. Antimicrobial Agents and Chemotherapy, 2015, 59, 1806-1810.	3.2	12
200	Immune Parameters for Diagnosis and Treatment Monitoring in Invasive Mold Infection. Journal of Fungi (Basel, Switzerland), 2019, 5, 116.	3.5	12
201	Antifungal susceptibility testing in Candida species: current methods and promising new tools for shortening the turnaround time. Expert Review of Anti-Infective Therapy, 2020, 18, 779-787.	4.4	12
202	Rapid Antifungal Susceptibility Testing of Yeasts and Molds by MALDI-TOF MS: A Systematic Review and Meta-Analysis. Journal of Fungi (Basel, Switzerland), 2021, 7, 63.	3.5	12
203	Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent <i>Candida</i> spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability. Antimicrobial Agents and Chemotherapy, 2021, 65, e0109321.	3.2	12
204	Dexamethasone Promotes Aspergillus fumigatus Growth in Macrophages by Triggering M2 Repolarization via Targeting PKM2. Journal of Fungi (Basel, Switzerland), 2021, 7, 70.	3.5	12
205	Triazole-resistant candidaemia following posaconazole exposure. International Journal of Antimicrobial Agents, 2009, 33, 494-495.	2.5	11
206	In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?. Current Infectious Disease Reports, 2010, 12, 401-408.	3.0	11
207	Biopsy Procedures for Molecular Tissue Diagnosis of Invasive Fungal Infections. Current Infectious Disease Reports, 2011, 13, 504-509.	3.0	11
208	Aspergillus terreus: How Inoculum Size and Host Characteristics Affect Its Virulence. Journal of Infectious Diseases, 2012, 205, 1192-1194.	4.0	11
209	Interaction of Platelets and Anidulafungin against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 626-628.	3.2	11
210	A nationwide passive surveillance on fungal infections shows a low burden of azole resistance in molds and yeasts in Tyrol, Austria. Infection, 2018, 46, 701-704.	4.7	11
211	Biofilm formation in clinically relevant filamentous fungi: a therapeutic challenge. Critical Reviews in Microbiology, 2022, 48, 197-221.	6.1	11
212	Wastewater surveillance of SARS-CoV-2 in Austria: development, implementation, and operation of the Tyrolean wastewater monitoring program. Journal of Water and Health, 2022, 20, 314-328.	2.6	11
213	<i>Aspergillus terreus</i> and the Interplay with Amphotericin B: from Resistance to Tolerance?. Antimicrobial Agents and Chemotherapy, 2022, 66, e0227421.	3.2	11
214	<i>In Vitro</i> Antifungal Susceptibility of Candida glabrata to Caspofungin and the Presence of <i>FKS</i> Mutations Correlate with Treatment Response in an Immunocompromised Murine Model of Invasive Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3646-3649.	3.2	10
215	Commercial Molecular Tests for Fungal Diagnosis from a Practical Point of View. Methods in Molecular Biology, 2017, 1508, 85-105.	0.9	10
216	Minimal Inhibitory Concentration (MIC)-Phenomena in Candida albicans and Their Impact on the Diagnosis of Antifungal Resistance. Journal of Fungi (Basel, Switzerland), 2019, 5, 83.	3.5	10

#	ARTICLE	IF	CITATIONS
217	Azole resistance in aspergillosis: The next threat?. <i>Current Fungal Infection Reports</i> , 2009, 3, 236-242.	2.6	9
218	Computed tomography guided percutaneous lung biopsies and suspected fungal infections in pediatric cancer patients. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1620-1624.	1.5	9
219	<i>In Vitro</i> Activities of Amphotericin B, Terbinafine, and Azole Drugs against Clinical and Environmental Isolates of <i>Aspergillus terreus</i> Sensu Stricto. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3619-3622.	3.2	9
220	Differential gene expression in <i>Aspergillus fumigatus</i> induced by human platelets in vitro. <i>International Journal of Medical Microbiology</i> , 2015, 305, 327-338.	3.6	9
221	Galactosaminogalactan secreted from <i>Aspergillus fumigatus</i> and <i>Aspergillus flavus</i> induces platelet activation. <i>Microbes and Infection</i> , 2020, 22, 331-339.	1.9	9
222	COVID-19 Associated Pulmonary Aspergillosis: Diagnostic Performance, Fungal Epidemiology and Antifungal Susceptibility. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 93.	3.5	9
223	Rep-PCR and RAPD-PCR fingerprinting of <i>Aspergillus terreus</i> . <i>Medical Mycology</i> , 2013, 51, 876-879.	0.7	8
224	Azole-resistant and -susceptible <i>Aspergillus fumigatus</i> isolates show comparable fitness and azole treatment outcome in immunocompetent mice. <i>Medical Mycology</i> , 2018, 56, 703-710.	0.7	8
225	European confederation of medical mycology expert consultâ€”An ECMM excellence center initiative. <i>Mycoses</i> , 2020, 63, 566-572.	4.0	8
226	Susceptibility Screening of Hyphae-Forming Fungi with a New, Easy, and Fast Inoculum Preparation Method. <i>Mycopathologia</i> , 2012, 174, 467-474.	3.1	7
227	Biliary amphotericin B pharmacokinetics and pharmacodynamics in critically ill liver transplant recipients receiving treatment with amphotericin B lipid formulations. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 325-331.	2.5	7
228	Impact of Morphological Sectors on Antifungal Susceptibility Testing and Virulence Studies. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	7
229	Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: An EFISG, IDWPâ€EBMT, EORTCâ€IDG and SEIFEM survey. <i>Mycoses</i> , 2020, 63, 420-429.	4.0	7
230	Which Type of Empiric Antibiotic Therapy is Appropriate? A 20-Year Retrospective Study of Bloodstream Infections in Childhood Cancer. <i>Infectious Diseases and Therapy</i> , 2021, 10, 789-800.	4.0	7
231	The Environmental Spread of <i>Aspergillus terreus</i> in Tyrol, Austria. <i>Microorganisms</i> , 2021, 9, 539.	3.6	7
232	Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools. <i>Mycopathologia</i> , 2016, 181, 561-566.	3.1	6
233	Nosocomial outbreak of extensively drug-resistant <i>Pseudomonas aeruginosa</i> associated with aromatherapy. <i>American Journal of Infection Control</i> , 2017, 45, 453-455.	2.3	6
234	Antibiotic resistance of blood cultures in regional and tertiary hospital settings of Tyrol, Austria (2006-2015): Impacts & trends. <i>PLoS ONE</i> , 2019, 14, e0223467.	2.5	6

#	ARTICLE	IF	CITATIONS
235	Genome Assemblies of Two Rare Opportunistic Yeast Pathogens: <i>Diutina rugosa</i> (syn. <i>Candida</i>) Tj ETQq1 Genetics, 2019, 9, 3921-3927.	1.0784314 1.8	14 6
236	Comparative immunopathogenesis in a murine model of inhalative infection with the mucormycetes <i>Lichtheimia corymbifera</i> and <i>Rhizopus arrhizus</i> . PLoS ONE, 2020, 15, e0234063.	2.5	6
237	<i>Aspergillus</i> -Derived Galactosaminogalactan Triggers Complement Activation on Human Platelets. Frontiers in Immunology, 2020, 11, 550827.	4.8	6
238	Pharmacokinetics and Antifungal Activity of Echinocandins in Ascites Fluid of Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, e0256520.	3.2	6
239	SARS-CoV-2â€“infected primary human airway epithelia illustrate mucus hypersecretion. Journal of Allergy and Clinical Immunology, 2021, 148, 909.	2.9	6
240	Complement Potentiates Immune Sensing of HIV-1 and Early Type I Interferon Responses. MBio, 2021, 12, e0240821.	4.1	6
241	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. Journal of Antimicrobial Chemotherapy, 2022, 77, 1209-1210.	3.0	6
242	Multiple colony antifungal susceptibility testing detects polyresistance in clinical <i>Candida</i> cultures: an ECMM Excellence centers study. Clinical Microbiology and Infection, 2022, , .	6.0	6
243	<i>Helicobacter pylori</i> infection and neopterin. Pteridines, 2001, 12, 126-129.	0.5	5
244	Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. Current Fungal Infection Reports, 2011, 5, 128-134.	2.6	5
245	Advances in the management of fungal infections. Mycoses, 2015, 58, 1-1.	4.0	5
246	Granulomatous encephalitis: protothecosis excluded?. Histopathology, 2016, 69, 1082-1084.	2.9	5
247	Immunological response to COVID-19 and its role as a predisposing factor in invasive aspergillosis. Current Medical Mycology, 2020, 6, 75-79.	0.8	5
248	Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium. Journal of Fungi (Basel, Switzerland), 2021, 7, 4.	3.5	5
249	Investigation of the effect of sustainable magnetic treatment on the microbiological communities in drinking water. Environmental Research, 2022, 213, 113638.	7.5	5
250	Why is biopsy of suspected fungal lung lesions necessary?. Medical Mycology Case Reports, 2013, 2, 141-143.	1.3	4
251	Dexamethasone Creates a Suppressive Microenvironment and Promotes <i>Aspergillus fumigatus</i> Invasion in a Human 3D Epithelial/Immune Respiratory Model. Journal of Fungi (Basel, Switzerland), 2021, 7, 221.	3.5	4
252	Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial. Expert Review of Anti-Infective Therapy, 2007, 5, 929-932.	4.4	3

#	ARTICLE	IF	CITATIONS
253	Reply to Garzoni and Dumont. <i>Clinical Infectious Diseases</i> , 2008, 46, 784-785.	5.8	3
254	Current evidence for the treatment of invasive fungal infections in immunocompromised patients. <i>Clinical Investigation</i> , 2011, 1, 447-457.	0.0	3
255	Multidrug- and Cross-Resistant <i>Candida</i> : the Looming Threat. <i>Current Fungal Infection Reports</i> , 2015, 9, 23-36.	2.6	3
256	Clinical Usefulness of Susceptibility Breakpoints for Yeasts in the Treatment of Candidemia: A Noninterventional Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 76.	3.5	3
257	Immunotherapy as an Antifungal Strategy in Immune Compromised Hosts. <i>Current Clinical Microbiology Reports</i> , 2020, 7, 57-66.	3.4	3
258	Longitudinal Evaluation of Plasma Cytokine Levels in Patients with Invasive Candidiasis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 101.	3.5	3
259	HIV protease inhibitors attenuate adherence of <i>Candida albicans</i> to epithelial cells in vitro. <i>FEMS Immunology and Medical Microbiology</i> , 2001, 31, 65-71.	2.7	3
260	Influence of Glucose on <i>Candida albicans</i> and the Relevance of the Complement FH-Binding Molecule Hgt1 in a Murine Model of Candidiasis. <i>Antibiotics</i> , 2022, 11, 257.	3.7	3
261	Isavuconazole: an orphan drug for treating invasive candidiasis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 333-342.	0.8	2
262	Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 572114.	4.8	2
263	Sepsis in Pediatric Cancer: Does Gender Matter? A 20-Year Retrospective Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 581-585.	4.0	2
264	1462Bronchoalveolar Lavage Lateral-Flow Device Test for Diagnosing Invasive Pulmonary Aspergillosis in ICU patients: a multicenter study. <i>Open Forum Infectious Diseases</i> , 2014, 1, S385-S386.	0.9	1
265	Hypoxia Decreases Diagnostic Biomarkers for Aspergillosis In Vitro. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 101.	3.5	1
266	Co- but not Sequential Infection of DCs Boosts Their HIV-Specific CTL-Stimulatory Capacity. <i>Frontiers in Immunology</i> , 2019, 10, 1123.	4.8	1
267	Echinocandins and Their Activity against <i>Aspergillus terreus</i> Species Complex: a Novel Agar Screening Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0190921.	3.2	1
268	Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2330-2335.	1.3	1
269	Diagnosing Aspergillosis: The Role of Invasive Diagnostic Interventions. , 2009, , 391-405.		0
270	Non-Culture-Based Methods for the Diagnosis of Invasive Candidiasis. <i>Current Fungal Infection Reports</i> , 2011, 5, 151-156.	2.6	0

#	ARTICLE	IF	CITATIONS
271	What paths are open for tackling increasing azole resistance in <i>Aspergillus</i> in the clinic?. Expert Review of Anti-Infective Therapy, 2012, 10, 1229-1231.	4.4	0
272	Control of hospital-acquired infections in Austria. Wiener Klinische Wochenschrift, 2018, 130, 673-679.	1.9	0
273	2104. Susceptibility Trends in Antifungal Resistance (STAR) Study: Preliminary Data from A New Prospective Antifungal Surveillance Study. Open Forum Infectious Diseases, 2019, 6, S712-S712.	0.9	0
274	2268. Clinical Implications of Azole-Resistant vs. Azole-Susceptible Invasive Aspergillosis in Hematological Malignancy (CLARITY): A Multicenter Study. Open Forum Infectious Diseases, 2019, 6, S776-S776.	0.9	0
275	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) – a multicenter study. Open Forum Infectious Diseases, 2020, 7, S795-S796.	0.9	0
276	Evaluation of Inoculum Preparation for Etest and EUCAST Broth Dilution to Detect Anidulafungin Polyresistance in <i>Candida glabrata</i> . Antimicrobial Agents and Chemotherapy, 0, , .	3.2	0